NEW YORK CITY, NY / ACCESS Newswire / April 22, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero" or "the ...

Uncertainties surrounding the U.S. pharmaceutical sector and the turbulent development in global stock markets have led to ...

A drug developed by US biotech Akero Therapeutics has hit the mark in a phase 2b trial in non-alcoholic steatohepatitis (NASH) – catapulting it to the forefront of efforts to find effective ...

For example, she bought Akero Therapeutics in January 2025—the same month the company announced promising results for its cirrhosis treatment. The stock initially shot up only to give back more ...

Akero Therapeutics nearly doubled Monday — and pulled 89bio shares higher — after the company's treatment for MASH obliterated expectations. SAN FRANCISCO, Jan. 27, 2025 (GLOBE NEWSWIRE ...

pre-fund Akero Therapeutics nearly doubled Monday — and pulled 89bio shares higher — after the company's treatment for MASH obliterated expectations. SAN FRANCISCO, Jan. 27, 2025 (GLOBE NEWSWIRE) -- ...

Around this time last year, Akero was riding high on positive phase 2b data for its candidate non-alcoholic steatohepatitis (NASH) therapy, but new data has dented optimism about the project.

The company will spotlight its latest advancements, including: RESET® and RESET-O®—the first and only FDA-authorized digital therapeutics for SUD and opioid use disorder (OUD). Watch the video ...